Side Effects Will Pressure Price Of Sanofi’s Zaltrap In Germany

Germany’s IQWiG could not fault Sanofi’s Zaltrap on clinical effectiveness in colorectal cancer, but its identification of serious adverse incidents is likely to depress the drug’s price there.